Cargando…

Treatment of hepatitis C virus genotype 4 in the DAA era

The recently approved interferon-free DAA (direct antiviral agents) regimens have shown not only to be effective in terms of sustained virological response (SVR) rates (> 90%) but also well tolerated in most hepatitis C virus (HCV) infected patients. Nevertheless HCV genotypes are different and o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Di Biagio, Antonio, Taramasso, Lucia, Cenderello, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251143/ https://www.ncbi.nlm.nih.gov/pubmed/30466446 http://dx.doi.org/10.1186/s12985-018-1094-4

Ejemplares similares

Treatment of hepatitis C in HIV patients in the new DAA era
por: Soriano, Vicente
Publicado: (2014)

Study of changes in lipid profile and insulin resistance in Egyptian patients with chronic hepatitis C genotype 4 in the era of DAAs
por: El Sagheer, Ghada, et al.
Publicado: (2018)

Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy
por: Drazilova, Sylvia, et al.
Publicado: (2018)

Bloodstream infections in patients living with HIV in the modern cART era
por: Taramasso, L., et al.
Publicado: (2019)

Therapeutic algorithms for chronic hepatitis C in the DAA era during the current economic crisis: whom to treat? How to treat? When to treat?
por: Petta, Salvatore, et al.
Publicado: (2012)

Telehealth for Hepatitis C Care in the DAA Era; Ensuring Everyone Can Access a Cure
por: Schulz, Thomas Ray, et al.
Publicado: (2017)

Treatment and re-treatment results of HCV patients in the DAA era
por: Piecha, Felix, et al.
Publicado: (2020)

Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST‐HCV cohort
por: Calvaruso, Vincenza, et al.
Publicado: (2021)

Treatment of Naïve Patients with Chronic Hepatitis C Genotypes 2 and 3 with Pegylated Interferon Alpha and Ribavirin in a Real World Setting: Relevance for the New Era of DAA
por: Heidrich, Benjamin, et al.
Publicado: (2014)

Molecular Mechanisms of Resistance to Direct-Acting Antiviral (DAA) Drugs for the Treatment of Hepatitis C Virus Infections
por: Izhari, Mohammad Asrar
Publicado: (2023)

Perceived Stress in Hepatitis C Virus Infected Patients under the DAA-Based Therapy
por: Danilescu, Claudia Monica, et al.
Publicado: (2022)

Is it still worthwhile to perform quarterly cd4+ t lymphocyte cell counts on hiv-1 infected stable patients?
por: Di Biagio, Antonio, et al.
Publicado: (2017)

Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis
por: Mangia, Alessandra, et al.
Publicado: (2018)

Depressive and Anxious Symptoms in Hepatitis C Virus Infected Patients Receiving DAA-Based Therapy
por: Danilescu, Claudia Monica, et al.
Publicado: (2021)

Ten Years of Medical Informatics and Standards Support for Clinical Research in an Infectious Diseases Network
por: Mora, Sara, et al.
Publicado: (2023)

Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study
por: Seo, Kwang Il, et al.
Publicado: (2017)

HCC in the Era of Direct-Acting Antiviral Agents (DAAs): Surgical and Other Curative or Palliative Strategies in the Elderly
por: Brozzetti, Stefania, et al.
Publicado: (2021)

Changing Landscape of Liver Transplantation in the Post-DAA and Contemporary ART Era
por: Saeed, Huma, et al.
Publicado: (2022)

310. Disparities in Hepatitis C Linkage to Care in the DAA Era: Findings from a Referral Clinic with an Embedded Nurse Navigator Model
por: Sherbuk, Jacqueline, et al.
Publicado: (2019)

On-site testing and case management to improve hepatitis C care in drug users: a prospective, longitudinal, multicenter study in the DAA era
por: Busschots, Dana, et al.
Publicado: (2021)

Assessing Patient Preferences for Treatment Decisions for New Direct Acting Antiviral (DAA) Therapies for Chronic Hepatitis C Virus Infections
por: Welzel, Tania M., et al.
Publicado: (2019)

Hepatocellular carcinoma occurrence in DAA-treated hepatitis C virus patients: Correlated or incidental? A brief review
por: Gigi, Eleni, et al.
Publicado: (2018)

Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV)
por: Walker, David R., et al.
Publicado: (2015)

The Impact of Hepatitis C Virus (HCV) Treatment with Direct-Acting (DAA) on the Incidence of Hepatocellular Carcinoma (HCC) in Patients with Advanced Liver Disease
por: De Comarmond, Charles, et al.
Publicado: (2017)

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
por: La Manna, Gaetano
Publicado: (2018)

“Waiting for DAAs”: A retrospective chart review of patients with untreated hepatitis C in Rwanda
por: Gupta, Neil, et al.
Publicado: (2017)

Time to change the single-centre approach to management of patients with tuberculosis: a novel network platform with automatic data import and data sharing
por: Riccardi, Niccolò, et al.
Publicado: (2018)

Treg cells in the course of chronic hepatitis C virus infection partially normalize in longitudinal observation after successful DAA treatment regardless of hepatic fibrosis stage
por: Zientarska, Agata, et al.
Publicado: (2021)

Management of hepatitis C genotype 4 in the directly acting antivirals era
por: Hathorn, Emma, et al.
Publicado: (2016)

Modeling-Based Response-Guided DAA Therapy for Chronic Hepatitis C to Identify Individuals for Shortening Treatment Duration
por: Goyal, Ashish, et al.
Publicado: (2022)

Vertical transmission of hepatitis C: towards universal antenatal screening in the era of new direct acting antivirals (DAAs)? Short review and analysis of the situation in Switzerland
por: Aebi-Popp, Karoline, et al.
Publicado: (2016)

Successful Treatment of Hepatitis C Virus Infection Using Direct-Acting Antiviral Agents (DAAs) in Adolescents with Kidney Transplantation: A Case Series
por: Ambarsari, Cahyani Gita, et al.
Publicado: (2020)

258 Analysis of the Hepatic Microenvironment Before and After Direct-Acting Antiviral (DAA) Therapy for Viral Hepatitis C
por: Millian, Daniel, et al.
Publicado: (2023)

Drug Resistance Profile and Clinical Features for Hepatitis C Patients Experiencing DAA Failure in Taiwan
por: Hong, Chun-Ming, et al.
Publicado: (2021)

Behandlung von Hepatitis-C-Infektionen im Zeitalter direkt wirkender antiviraler Medikamente (DAAs)
por: Peiffer, Kai-Henrik, et al.
Publicado: (2022)

A real-life study of the positive response to DAA-based therapies for hepatitis C in Brazil
por: Vivaldini, Simone Monzani, et al.
Publicado: (2021)

The New Era of Hepatitis C Virus Therapy
por: Al-Judaibi, Bandar
Publicado: (2015)

Clinical outcomes of DAA and related techniques in hip arthroplasty
por: Driesman, Adam, et al.
Publicado: (2023)

Hepatitis C Virus: Viral Quasispecies and Genotypes
por: Tsukiyama-Kohara, Kyoko, et al.
Publicado: (2017)

The continuum of hepatitis C care for criminal justice involved adults in the DAA era: a retrospective cohort study demonstrating limited treatment uptake and inconsistent linkage to community-based care
por: Hochstatter, Karli R., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_l9k1ktqanfe1vlhsq02e27e6gs